Page last updated: 2024-10-15

bim 23a760

Description

TBR-760: has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID154584814
CHEMBL ID4650342
MeSH IDM0524611

Synonyms (12)

Synonym
dopastatin
l32im11dv4 ,
bim-23a760
l-threoninamide, n2,n6-bis(2-((((8.beta.)-6-propylergolin-8-yl)methyl)thio)acetyl)-d-lysyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-(2s)-2-aminobutanoyl-l-cysteinyl-, cyclic (2->7)-disulfide
onzigolide [inn]
l-threoninamide, n2,n6-bis(((((8.beta.)-6-propylergolin-8-yl)methyl)thio)acetyl)-d-lysyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-(2s)-2-aminobutanoyl-l-cysteinyl-, cyclic (2->7)-disulfide
tbr-760
onzigolide
778630-77-6
HY-P3294
CHEMBL4650342
CS-0213566

Dosage Studied

ExcerptReference
" Dose-response studies in 2D and 3D human pancreatic NET cell cultures (BON-1 and QGP-1) were performed under serum-containing and serum-deprived conditions."( Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Culler, MD; de Herder, WW; Dogan-Oruc, F; Feelders, RA; Herrera-Martínez, AD; Hofland, LJ; Luque, RM; van den Dungen, R; van Koetsveld, PM, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (15.79)29.6817
2010's14 (73.68)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews6 (28.57%)6.00%
Case Studies1 (4.76%)4.05%
Observational0 (0.00%)0.25%
Other13 (61.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]